Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Travere Therapeutics, Inc.
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease focal segmental glomerulosclerosis (FSGS). The company's already ...
The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $50.45 / share. This is an ...
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Merck & Company, with a price target of $140.00. Claim 55% Off TipRanks. Unlock hedge fund-l ...
Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five ...
Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...
Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.
The Summers Value Fund LP returned 6.7% net in 2025, trailing Russell 2000 Index ETF, which returned 12.7%, and Russell 2000 ...
Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results